Your browser is no longer supported. Please, upgrade your browser.
Settings
TROV TrovaGene, Inc. daily Stock Chart
TROV [NASD]
TrovaGene, Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own0.80% Shs Outstand29.96M Perf Week0.00%
Market Cap67.41M Forward P/E- EPS next Y-1.11 Insider Trans16.94% Shs Float27.66M Perf Month7.14%
Income-38.10M PEG- EPS next Q-0.33 Inst Own26.90% Short Float8.50% Perf Quarter-47.06%
Sales0.40M P/S168.53 EPS this Y-38.30% Inst Trans-9.37% Short Ratio6.84 Perf Half Y-54.82%
Book/sh0.88 P/B2.56 EPS next Y17.80% ROA-61.60% Target Price6.23 Perf Year-32.84%
Cash/sh1.57 P/C1.43 EPS next 5Y- ROE-102.00% 52W Range1.77 - 6.93 Perf YTD7.14%
Dividend- P/FCF- EPS past 5Y-6.50% ROI-38.80% 52W High-67.53% Beta0.80
Dividend %- Quick Ratio7.30 Sales past 5Y3.30% Gross Margin- 52W Low26.76% ATR0.18
Employees72 Current Ratio7.30 Sales Q/Q0.00% Oper. Margin- RSI (14)43.58 Volatility4.43% 7.88%
OptionableYes Debt/Eq0.61 EPS Q/Q-250.10% Profit Margin- Rel Volume0.60 Prev Close2.35
ShortableYes LT Debt/Eq0.58 EarningsFeb 08 AMC Payout- Avg Volume344.04K Price2.25
Recom2.50 SMA20-0.88% SMA50-14.24% SMA200-47.07% Volume206,613 Change-4.26%
Aug-08-16Upgrade Cantor Fitzgerald Hold → Buy
Aug-05-16Reiterated Maxim Group Buy $12 → $9
Jul-07-16Initiated Maxim Group Buy $12
Apr-26-16Downgrade Leerink Partners Outperform → Mkt Perform
Apr-25-16Downgrade Piper Jaffray Overweight → Neutral
Apr-25-16Downgrade Cantor Fitzgerald Buy → Hold $9 → $5
Feb-03-16Reiterated Maxim Group Buy $13 → $12
Sep-16-15Initiated Cantor Fitzgerald Buy
Aug-14-15Initiated Leerink Partners Outperform
Apr-20-15Reiterated Maxim Group Buy $10 → $13
Jul-10-14Initiated Maxim Group Buy $10
Nov-13-13Reiterated Aegis Capital Buy $14 → $10
Oct-01-13Reiterated Aegis Capital Buy $14
Jul-16-13Initiated Cantor Fitzgerald Buy $10
Apr-01-13Reiterated Aegis Capital Buy $12 → $14
Dec-12-12Initiated Aegis Capital Buy $12
Jan-12-17 11:59AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  Trovagene Announces Broadening Network of Commercial Distributors PR Newswire
Jan-09-17 06:06AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
Dec-19-16 02:20PM  ETFs with exposure to TrovaGene, Inc. : December 19, 2016
Dec-15-16 06:30AM  Trovagene to Focus More on Liquid Biopsy Testing Market
Dec-13-16 05:01PM  TROVAGENE, INC. Files SEC form 8-K, Other Events
04:05PM  Trovagene announces a reorganization to accelerate global distribution of liquid biopsy technology PR Newswire
Dec-08-16 03:24PM  ETFs with exposure to TrovaGene, Inc. : December 8, 2016 +15.22%
Dec-01-16 08:31AM  TrovaGene Inks Contract with Boreal Genomics, Stock Down -12.07%
Nov-30-16 08:20AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  Trovagene and Boreal Genomics Announce Strategic Partnership PR Newswire
Nov-29-16 08:56AM  TrovaGene (TROV) Precision Cancer Monitoring Data Positive
Nov-28-16 08:26AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:00AM  World Lung Conference Features Data Demonstrating Clinical Utility and Cost Effectiveness of Trovagene's Liquid Biopsy Tests for Mutation Detection and Monitoring in NSCLC Patients PR Newswire
Nov-22-16 08:43AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:00AM  Trovagene to Attend the 28th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-17-16 01:04PM  TROVAGENE, INC. Financials
Nov-16-16 01:30PM  ETFs with exposure to TrovaGene, Inc. : November 16, 2016 +8.47%
Nov-14-16 11:31AM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
Nov-10-16 08:23AM  TrovaGene (TROV) Reports Wider-than-Expected Loss in Q3 -15.19%
12:12AM  Edited Transcript of TROV earnings conference call or presentation 9-Nov-16 10:00pm GMT
Nov-09-16 04:21PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition +11.27%
04:11PM  Trovagene reports 3Q loss
04:01PM  Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments PR Newswire
04:00PM  TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report
07:07AM  Q3 2016 Trovagene Inc Earnings Release - 4:00 pm ET
Nov-07-16 08:26AM  TROVAGENE, INC. Files SEC form 8-K, Other Events +9.09%
08:00AM  Trovagene Announces HPV Patent Issuance by U.S. Patent and Trademark Office, Broadening Its Precision Cancer Monitoring IP Portfolio PR Newswire
Nov-02-16 05:12PM  Trovagene Schedules Release of Third Quarter 2016 Financial Results and Investor Conference Call PR Newswire -7.35%
05:02PM  TROVAGENE, INC. Files SEC form 8-K, Other Events
Oct-17-16 10:30AM  Trovagene to Present at the BIO Investor Forum in San Francisco on October 19 PR Newswire
Oct-05-16 08:42AM  Trovagene's Liquid Biopsy to Participate in Precision Promise
Oct-04-16 08:29AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
06:00AM  Trovagene's Liquid Biopsy in Groundbreaking National Initiative to Transform Outcomes for Pancreatic Cancer Patients PR Newswire
Sep-30-16 10:10AM  ETFs with exposure to TrovaGene, Inc. : September 30, 2016
Sep-26-16 06:04AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-12-16 12:00PM  ETFs with exposure to TrovaGene, Inc. : September 12, 2016
Sep-09-16 09:03AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.05%
08:30AM  Trovagene to Present at the 3rd Annual Precision Medicine Congress PR Newswire
Aug-31-16 11:56AM  ETFs with exposure to TrovaGene, Inc. : August 31, 2016
Aug-17-16 10:50AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:30AM  Blue Cross Blue Shield Illinois to Cover Trovera Liquid Biopsy Tests PR Newswire
Aug-16-16 12:47PM  ETFs with exposure to TrovaGene, Inc. : August 16, 2016
Aug-15-16 01:42PM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016
Aug-09-16 11:01AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:34AM  Trovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference PR Newswire
08:30AM  Trovera Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report in Non-Small Cell Lung Cancer PR Newswire
Aug-08-16 07:29AM  TrovaGene upgraded by Cantor Fitzgerald
Aug-06-16 02:21PM  Edited Transcript of TROV earnings conference call or presentation 4-Aug-16 9:00pm GMT
Aug-05-16 08:33AM  TrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise -5.63%
Aug-04-16 07:37PM  Trovagene reports 2Q loss
05:12PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:15PM  Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments PR Newswire
04:09PM  TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report
07:07AM  Q2 2016 Trovagene Inc Earnings Release - 4:00 pm ET
Aug-01-16 10:11AM  Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Jul-26-16 04:32PM  TROVAGENE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga
08:45AM  Trovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call PR Newswire
08:30AM  Diagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology PR Newswire
Jul-13-16 06:05PM  TrovaGene Inks Partnership with USC Norris Cancer Center
Jul-12-16 10:49AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:30AM  Trovagene and USC Norris Comprehensive Cancer Center Collaborate to Standardize the Use of Trovera ctDNA Liquid Biopsy Tests in Patient Care PR Newswire
Jul-11-16 10:45AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:42AM  /C O R R E C T I O N -- Trovagene, Inc./ PR Newswire
Jul-07-16 04:31PM  TrovaGene Inks Partnership with University of Michigan +6.89%
Jul-06-16 10:51AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
09:58AM  Trovagene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer PR Newswire
Jul-05-16 07:34PM  Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference PR Newswire
Jun-24-16 05:48PM  ETFs with exposure to TrovaGene, Inc. : June 24, 2016 -5.21%
Jun-10-16 04:37AM  TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised) -12.30%
Jun-07-16 09:39AM  TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive
Jun-06-16 11:16AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
11:00AM  ASCO Oral Presentation Demonstrates Trovagene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer PR Newswire
Jun-03-16 03:45PM  ETFs with exposure to TrovaGene, Inc. : June 3, 2016
May-20-16 12:12PM  ETFs with exposure to TrovaGene, Inc. : May 20, 2016
May-19-16 02:50PM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q1, 2016 By the Numbers
08:48AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:05AM  Large Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting PR Newswire
May-18-16 04:32PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers +7.30%
May-17-16 04:33PM  TROVAGENE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +5.12%
May-13-16 04:44PM  TROVAGENE, INC. Files SEC form 8-K, Other Events +9.86%
08:05AM  Large Clinical Study Demonstrates High Detection Rate and Ability to Monitor KRAS Mutations in Pancreatic Cancer Patients; Results Presented at 2016 AACR Pancreatic Cancer Meeting PR Newswire
May-11-16 08:16AM  TrovaGene (TROV) Q1 Loss Wider than Expected, Stock Gains
May-10-16 10:35PM  Edited Transcript of TROV earnings conference call or presentation 10-May-16 9:00pm GMT
06:09PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition
05:25PM  Trovagene reports 1Q loss
04:15PM  TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
04:05PM  Trovagene Announces First Quarter 2016 Financial Results PR Newswire
07:07AM  Q1 2016 Trovagene Inc Earnings Release - 4:00 pm ET CCBN
May-05-16 01:13PM  Lifshitz & Miller Law Firm Announces Investigation of Apigee Corporation, Mentor Graphics Corp., PayPal Holdings Inc., Performance Sports Group, Ltd., PJT Partners, Inc., and Trovagene, Inc. PR Newswire +5.45%
May-03-16 08:15AM  Trovagene Schedules Release of First Quarter 2016 Financial Results and Investor Conference Call PR Newswire -6.02%
Apr-28-16 08:15AM  Trovagene to Present at the 41st Annual Deutsche Bank Healthcare Conference PR Newswire -6.31%
Apr-27-16 05:18PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
09:16AM  What's in Store for TrovaGene (TROV) this Earnings Season? Zacks
Apr-25-16 04:48PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online -23.83%
08:05AM  Trovagene Appoints Bill Welch as Chief Executive Officer PR Newswire
Apr-15-16 02:02PM  Trovagene Gains 3% On Favorable Mention In Medical Journal
08:17AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:15AM  Patient Case Report Demonstrating the Ability of Trovagene's Precision Cancer Monitoring Platform to Determine Early Drug Response Published in Cancer Discovery PR Newswire
Apr-12-16 01:10PM  TrovaGene Inks Strategic Partnership with Stratose, Stock Up
Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, a cell-free molecular diagnostic platform that provides cancer monitoring by tracking and quantifying levels of cell-free DNA from either urine or blood samples, as well as intends to provide clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung cancer, as well as targeting clinically validated gene rearrangements, such as ALK, RET, and ROS. In addition, it offers laboratory developed tests for oncogene mutations to end users through a sales and marketing organization. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Erlander MarkChief Scientific OfficerJan 02Option Exercise0.0050,000055,000Jan 04 05:01 PM
Tennant StanleyDirectorDec 19Buy2.1010,00021,000217,728Dec 19 04:51 PM
Tennant StanleyDirectorDec 16Buy2.0014,96629,932207,728Dec 19 06:04 AM
WELCH WILLIAM JCEODec 16Buy2.094,7509,9444,750Dec 19 01:49 PM
Erlander MarkChief Scientific OfficerDec 14Buy2.085,00010,3755,000Dec 15 05:00 PM
ZANIBONI STEVEFormer CFOApr 21Option Exercise3.6575,639275,86696,968Apr 22 04:05 PM